J CANCER RES CLIN 润色咨询

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

出版年份:1979 年文章数:3146 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:2.8% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿,10月7日直接接收,还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=471, replyNumber=124, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:Part 1 审稿流程 Part 2 论坛常见问题 审稿流程如下: 2023-06-20 投稿 2023-06-20 技术检查通过,安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受 后续包括编辑初步校对,选择OA还是非OA,最后校对都是在2、3天内完成,效率很高 常见问题 1、文章参考格式:Endnote APA 6th(稍微参考一下既往杂志文章都不会问出这问题) 2、投稿状态的顺序:Under review(稿件进入投稿流程)→Reviewer Accepted(有审稿人开始审你的稿件了)→Reviews report received(编辑收到了审稿人的意见)→Reviewer reports received/ Ready for editor' s decision(所有的审稿人意见都回来之后,才会开始进入编辑审查阶段,等待编辑汇总意见之后会发给你对文章的处理决定) 3、回顾性研究,case report,基础,生信,meta都收录,被秒拒的大多是优先级不够或者没有任何亮点,纯生信不加试验没有亮点凭啥接收呢?杂志审稿人态度还是很端正的,结合审稿意见来看对文章的大方向和细节都是有要求的,没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上,在投稿时把那个选项X掉比较好 5、杂志可以共同通讯,在文章中标注清楚即可 6、在进入审稿流程后,所有的文章动态更新都只有通讯作者邮箱才能收到,第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别,OA文章在增加引用量上有其固有优势,掏钱发文章这种事见仁见智,btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向:肿瘤<br>经验分享:我的文章13号接收的,回来看评论,很多朋友都在问参考文献格式怎么下,说实话,到现在文章被接收我都不知道哪里下,我当时投稿的时候也是找了半天没找到,后来索性找了个施普林格旗下比较类似的文献格式,然后用endnote编辑成JOCR这个样子的,然后投稿了,到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218438, encodeId=49f11218438ff, content=偏重的研究方向:肿瘤;眼科<br>经验分享:2022.5.5晚10点投稿<br>2022.5.6 Quality check passed <br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d564883189, createdName=18344b9fa1m, createdTime=Tue May 10 13:43:22 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向:肝癌<br>经验分享:刚刚一个月 还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2153998, encodeId=04b2215399869, content=偏重的研究方向:肿瘤;胰腺癌<br>经验分享:三周半了还没有邀请到审稿人,肿瘤基础研究,看大家最近都表示审稿人邀请比较慢,想咨询一下后续进度,大概多久能邀请到呢?后续被拒的概率大不大,好怕再等又被拒了,时间紧张。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5468757151, createdName=ms7000001668893774, createdTime=Tue Aug 22 08:50:22 CST 2023, time=2023-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:5.2投稿,5.4技术审查通过;5.4under review;5.9小修,5.11修回,5.12技术审查通过;5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受,因为杂志效率高所以投了,没上5分是个遗憾,写一下时间线吧,贡大家参考<br>临床回顾研究,头颈肿瘤 主编和副编效率一流,审稿人效率也是见过最快的,初审14天,二审7天<br>2021-8-27 new submission<br>2021-9-20 minor revisions<br>2021-10-11 Revision Submitted<br>2021-10-24 reviews completed <br>2021-10-24 editor assigned<br>2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157814, encodeId=e6ed215e81465, content=变成editor appointed的留言统计一下吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57435640187, createdName=koko叩叩, createdTime=Fri Sep 15 10:43:01 CST 2023, time=2023-09-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154512, encodeId=7e702154512b4, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信加细胞功能实验<br>经验分享:8月4号已投稿,8月5号邀请6个审稿人,8月14号1个审稿人接受审稿,现在没消息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=ms8000001459205604, createdTime=Fri Aug 25 11:04:29 CST 2023, time=2023-08-25, status=1, ipAttribution=广西)]
    2020-06-12 ms5502585941462392

    9月28投稿,10月7日直接接收,还以为是拒稿。😀

    124

    展开124条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿,10月7日直接接收,还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=471, replyNumber=124, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:Part 1 审稿流程 Part 2 论坛常见问题 审稿流程如下: 2023-06-20 投稿 2023-06-20 技术检查通过,安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受 后续包括编辑初步校对,选择OA还是非OA,最后校对都是在2、3天内完成,效率很高 常见问题 1、文章参考格式:Endnote APA 6th(稍微参考一下既往杂志文章都不会问出这问题) 2、投稿状态的顺序:Under review(稿件进入投稿流程)→Reviewer Accepted(有审稿人开始审你的稿件了)→Reviews report received(编辑收到了审稿人的意见)→Reviewer reports received/ Ready for editor' s decision(所有的审稿人意见都回来之后,才会开始进入编辑审查阶段,等待编辑汇总意见之后会发给你对文章的处理决定) 3、回顾性研究,case report,基础,生信,meta都收录,被秒拒的大多是优先级不够或者没有任何亮点,纯生信不加试验没有亮点凭啥接收呢?杂志审稿人态度还是很端正的,结合审稿意见来看对文章的大方向和细节都是有要求的,没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上,在投稿时把那个选项X掉比较好 5、杂志可以共同通讯,在文章中标注清楚即可 6、在进入审稿流程后,所有的文章动态更新都只有通讯作者邮箱才能收到,第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别,OA文章在增加引用量上有其固有优势,掏钱发文章这种事见仁见智,btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向:肿瘤<br>经验分享:我的文章13号接收的,回来看评论,很多朋友都在问参考文献格式怎么下,说实话,到现在文章被接收我都不知道哪里下,我当时投稿的时候也是找了半天没找到,后来索性找了个施普林格旗下比较类似的文献格式,然后用endnote编辑成JOCR这个样子的,然后投稿了,到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218438, encodeId=49f11218438ff, content=偏重的研究方向:肿瘤;眼科<br>经验分享:2022.5.5晚10点投稿<br>2022.5.6 Quality check passed <br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d564883189, createdName=18344b9fa1m, createdTime=Tue May 10 13:43:22 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向:肝癌<br>经验分享:刚刚一个月 还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2153998, encodeId=04b2215399869, content=偏重的研究方向:肿瘤;胰腺癌<br>经验分享:三周半了还没有邀请到审稿人,肿瘤基础研究,看大家最近都表示审稿人邀请比较慢,想咨询一下后续进度,大概多久能邀请到呢?后续被拒的概率大不大,好怕再等又被拒了,时间紧张。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5468757151, createdName=ms7000001668893774, createdTime=Tue Aug 22 08:50:22 CST 2023, time=2023-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:5.2投稿,5.4技术审查通过;5.4under review;5.9小修,5.11修回,5.12技术审查通过;5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受,因为杂志效率高所以投了,没上5分是个遗憾,写一下时间线吧,贡大家参考<br>临床回顾研究,头颈肿瘤 主编和副编效率一流,审稿人效率也是见过最快的,初审14天,二审7天<br>2021-8-27 new submission<br>2021-9-20 minor revisions<br>2021-10-11 Revision Submitted<br>2021-10-24 reviews completed <br>2021-10-24 editor assigned<br>2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157814, encodeId=e6ed215e81465, content=变成editor appointed的留言统计一下吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57435640187, createdName=koko叩叩, createdTime=Fri Sep 15 10:43:01 CST 2023, time=2023-09-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154512, encodeId=7e702154512b4, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信加细胞功能实验<br>经验分享:8月4号已投稿,8月5号邀请6个审稿人,8月14号1个审稿人接受审稿,现在没消息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=ms8000001459205604, createdTime=Fri Aug 25 11:04:29 CST 2023, time=2023-08-25, status=1, ipAttribution=广西)]
    2023-08-03 ms1000001633014790 来自陕西省

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向:肿瘤
    经验分享:Part 1 审稿流程 Part 2 论坛常见问题 审稿流程如下: 2023-06-20 投稿 2023-06-20 技术检查通过,安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受 后续包括编辑初步校对,选择OA还是非OA,最后校对都是在2、3天内完成,效率很高 常见问题 1、文章参考格式:Endnote APA 6th(稍微参考一下既往杂志文章都不会问出这问题) 2、投稿状态的顺序:Under review(稿件进入投稿流程)→Reviewer Accepted(有审稿人开始审你的稿件了)→Reviews report received(编辑收到了审稿人的意见)→Reviewer reports received/ Ready for editor' s decision(所有的审稿人意见都回来之后,才会开始进入编辑审查阶段,等待编辑汇总意见之后会发给你对文章的处理决定) 3、回顾性研究,case report,基础,生信,meta都收录,被秒拒的大多是优先级不够或者没有任何亮点,纯生信不加试验没有亮点凭啥接收呢?杂志审稿人态度还是很端正的,结合审稿意见来看对文章的大方向和细节都是有要求的,没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上,在投稿时把那个选项X掉比较好 5、杂志可以共同通讯,在文章中标注清楚即可 6、在进入审稿流程后,所有的文章动态更新都只有通讯作者邮箱才能收到,第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别,OA文章在增加引用量上有其固有优势,掏钱发文章这种事见仁见智,btw这个杂志APC偏贵

    34

    展开34条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿,10月7日直接接收,还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=471, replyNumber=124, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:Part 1 审稿流程 Part 2 论坛常见问题 审稿流程如下: 2023-06-20 投稿 2023-06-20 技术检查通过,安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受 后续包括编辑初步校对,选择OA还是非OA,最后校对都是在2、3天内完成,效率很高 常见问题 1、文章参考格式:Endnote APA 6th(稍微参考一下既往杂志文章都不会问出这问题) 2、投稿状态的顺序:Under review(稿件进入投稿流程)→Reviewer Accepted(有审稿人开始审你的稿件了)→Reviews report received(编辑收到了审稿人的意见)→Reviewer reports received/ Ready for editor' s decision(所有的审稿人意见都回来之后,才会开始进入编辑审查阶段,等待编辑汇总意见之后会发给你对文章的处理决定) 3、回顾性研究,case report,基础,生信,meta都收录,被秒拒的大多是优先级不够或者没有任何亮点,纯生信不加试验没有亮点凭啥接收呢?杂志审稿人态度还是很端正的,结合审稿意见来看对文章的大方向和细节都是有要求的,没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上,在投稿时把那个选项X掉比较好 5、杂志可以共同通讯,在文章中标注清楚即可 6、在进入审稿流程后,所有的文章动态更新都只有通讯作者邮箱才能收到,第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别,OA文章在增加引用量上有其固有优势,掏钱发文章这种事见仁见智,btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向:肿瘤<br>经验分享:我的文章13号接收的,回来看评论,很多朋友都在问参考文献格式怎么下,说实话,到现在文章被接收我都不知道哪里下,我当时投稿的时候也是找了半天没找到,后来索性找了个施普林格旗下比较类似的文献格式,然后用endnote编辑成JOCR这个样子的,然后投稿了,到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218438, encodeId=49f11218438ff, content=偏重的研究方向:肿瘤;眼科<br>经验分享:2022.5.5晚10点投稿<br>2022.5.6 Quality check passed <br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d564883189, createdName=18344b9fa1m, createdTime=Tue May 10 13:43:22 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向:肝癌<br>经验分享:刚刚一个月 还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2153998, encodeId=04b2215399869, content=偏重的研究方向:肿瘤;胰腺癌<br>经验分享:三周半了还没有邀请到审稿人,肿瘤基础研究,看大家最近都表示审稿人邀请比较慢,想咨询一下后续进度,大概多久能邀请到呢?后续被拒的概率大不大,好怕再等又被拒了,时间紧张。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5468757151, createdName=ms7000001668893774, createdTime=Tue Aug 22 08:50:22 CST 2023, time=2023-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:5.2投稿,5.4技术审查通过;5.4under review;5.9小修,5.11修回,5.12技术审查通过;5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受,因为杂志效率高所以投了,没上5分是个遗憾,写一下时间线吧,贡大家参考<br>临床回顾研究,头颈肿瘤 主编和副编效率一流,审稿人效率也是见过最快的,初审14天,二审7天<br>2021-8-27 new submission<br>2021-9-20 minor revisions<br>2021-10-11 Revision Submitted<br>2021-10-24 reviews completed <br>2021-10-24 editor assigned<br>2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157814, encodeId=e6ed215e81465, content=变成editor appointed的留言统计一下吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57435640187, createdName=koko叩叩, createdTime=Fri Sep 15 10:43:01 CST 2023, time=2023-09-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154512, encodeId=7e702154512b4, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信加细胞功能实验<br>经验分享:8月4号已投稿,8月5号邀请6个审稿人,8月14号1个审稿人接受审稿,现在没消息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=ms8000001459205604, createdTime=Fri Aug 25 11:04:29 CST 2023, time=2023-08-25, status=1, ipAttribution=广西)]
    2021-12-19 解忧

    偏重的研究方向:肿瘤
    经验分享:我的文章13号接收的,回来看评论,很多朋友都在问参考文献格式怎么下,说实话,到现在文章被接收我都不知道哪里下,我当时投稿的时候也是找了半天没找到,后来索性找了个施普林格旗下比较类似的文献格式,然后用endnote编辑成JOCR这个样子的,然后投稿了,到现在接收了也没有什么问题

    32

    展开32条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿,10月7日直接接收,还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=471, replyNumber=124, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:Part 1 审稿流程 Part 2 论坛常见问题 审稿流程如下: 2023-06-20 投稿 2023-06-20 技术检查通过,安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受 后续包括编辑初步校对,选择OA还是非OA,最后校对都是在2、3天内完成,效率很高 常见问题 1、文章参考格式:Endnote APA 6th(稍微参考一下既往杂志文章都不会问出这问题) 2、投稿状态的顺序:Under review(稿件进入投稿流程)→Reviewer Accepted(有审稿人开始审你的稿件了)→Reviews report received(编辑收到了审稿人的意见)→Reviewer reports received/ Ready for editor' s decision(所有的审稿人意见都回来之后,才会开始进入编辑审查阶段,等待编辑汇总意见之后会发给你对文章的处理决定) 3、回顾性研究,case report,基础,生信,meta都收录,被秒拒的大多是优先级不够或者没有任何亮点,纯生信不加试验没有亮点凭啥接收呢?杂志审稿人态度还是很端正的,结合审稿意见来看对文章的大方向和细节都是有要求的,没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上,在投稿时把那个选项X掉比较好 5、杂志可以共同通讯,在文章中标注清楚即可 6、在进入审稿流程后,所有的文章动态更新都只有通讯作者邮箱才能收到,第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别,OA文章在增加引用量上有其固有优势,掏钱发文章这种事见仁见智,btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向:肿瘤<br>经验分享:我的文章13号接收的,回来看评论,很多朋友都在问参考文献格式怎么下,说实话,到现在文章被接收我都不知道哪里下,我当时投稿的时候也是找了半天没找到,后来索性找了个施普林格旗下比较类似的文献格式,然后用endnote编辑成JOCR这个样子的,然后投稿了,到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218438, encodeId=49f11218438ff, content=偏重的研究方向:肿瘤;眼科<br>经验分享:2022.5.5晚10点投稿<br>2022.5.6 Quality check passed <br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d564883189, createdName=18344b9fa1m, createdTime=Tue May 10 13:43:22 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向:肝癌<br>经验分享:刚刚一个月 还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2153998, encodeId=04b2215399869, content=偏重的研究方向:肿瘤;胰腺癌<br>经验分享:三周半了还没有邀请到审稿人,肿瘤基础研究,看大家最近都表示审稿人邀请比较慢,想咨询一下后续进度,大概多久能邀请到呢?后续被拒的概率大不大,好怕再等又被拒了,时间紧张。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5468757151, createdName=ms7000001668893774, createdTime=Tue Aug 22 08:50:22 CST 2023, time=2023-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:5.2投稿,5.4技术审查通过;5.4under review;5.9小修,5.11修回,5.12技术审查通过;5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受,因为杂志效率高所以投了,没上5分是个遗憾,写一下时间线吧,贡大家参考<br>临床回顾研究,头颈肿瘤 主编和副编效率一流,审稿人效率也是见过最快的,初审14天,二审7天<br>2021-8-27 new submission<br>2021-9-20 minor revisions<br>2021-10-11 Revision Submitted<br>2021-10-24 reviews completed <br>2021-10-24 editor assigned<br>2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157814, encodeId=e6ed215e81465, content=变成editor appointed的留言统计一下吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57435640187, createdName=koko叩叩, createdTime=Fri Sep 15 10:43:01 CST 2023, time=2023-09-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154512, encodeId=7e702154512b4, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信加细胞功能实验<br>经验分享:8月4号已投稿,8月5号邀请6个审稿人,8月14号1个审稿人接受审稿,现在没消息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=ms8000001459205604, createdTime=Fri Aug 25 11:04:29 CST 2023, time=2023-08-25, status=1, ipAttribution=广西)]
    2022-05-10 18344b9fa1m

    偏重的研究方向:肿瘤;眼科
    经验分享:2022.5.5晚10点投稿
    2022.5.6 Quality check passed

    31

    展开31条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿,10月7日直接接收,还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=471, replyNumber=124, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:Part 1 审稿流程 Part 2 论坛常见问题 审稿流程如下: 2023-06-20 投稿 2023-06-20 技术检查通过,安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受 后续包括编辑初步校对,选择OA还是非OA,最后校对都是在2、3天内完成,效率很高 常见问题 1、文章参考格式:Endnote APA 6th(稍微参考一下既往杂志文章都不会问出这问题) 2、投稿状态的顺序:Under review(稿件进入投稿流程)→Reviewer Accepted(有审稿人开始审你的稿件了)→Reviews report received(编辑收到了审稿人的意见)→Reviewer reports received/ Ready for editor' s decision(所有的审稿人意见都回来之后,才会开始进入编辑审查阶段,等待编辑汇总意见之后会发给你对文章的处理决定) 3、回顾性研究,case report,基础,生信,meta都收录,被秒拒的大多是优先级不够或者没有任何亮点,纯生信不加试验没有亮点凭啥接收呢?杂志审稿人态度还是很端正的,结合审稿意见来看对文章的大方向和细节都是有要求的,没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上,在投稿时把那个选项X掉比较好 5、杂志可以共同通讯,在文章中标注清楚即可 6、在进入审稿流程后,所有的文章动态更新都只有通讯作者邮箱才能收到,第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别,OA文章在增加引用量上有其固有优势,掏钱发文章这种事见仁见智,btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向:肿瘤<br>经验分享:我的文章13号接收的,回来看评论,很多朋友都在问参考文献格式怎么下,说实话,到现在文章被接收我都不知道哪里下,我当时投稿的时候也是找了半天没找到,后来索性找了个施普林格旗下比较类似的文献格式,然后用endnote编辑成JOCR这个样子的,然后投稿了,到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218438, encodeId=49f11218438ff, content=偏重的研究方向:肿瘤;眼科<br>经验分享:2022.5.5晚10点投稿<br>2022.5.6 Quality check passed <br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d564883189, createdName=18344b9fa1m, createdTime=Tue May 10 13:43:22 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向:肝癌<br>经验分享:刚刚一个月 还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2153998, encodeId=04b2215399869, content=偏重的研究方向:肿瘤;胰腺癌<br>经验分享:三周半了还没有邀请到审稿人,肿瘤基础研究,看大家最近都表示审稿人邀请比较慢,想咨询一下后续进度,大概多久能邀请到呢?后续被拒的概率大不大,好怕再等又被拒了,时间紧张。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5468757151, createdName=ms7000001668893774, createdTime=Tue Aug 22 08:50:22 CST 2023, time=2023-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:5.2投稿,5.4技术审查通过;5.4under review;5.9小修,5.11修回,5.12技术审查通过;5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受,因为杂志效率高所以投了,没上5分是个遗憾,写一下时间线吧,贡大家参考<br>临床回顾研究,头颈肿瘤 主编和副编效率一流,审稿人效率也是见过最快的,初审14天,二审7天<br>2021-8-27 new submission<br>2021-9-20 minor revisions<br>2021-10-11 Revision Submitted<br>2021-10-24 reviews completed <br>2021-10-24 editor assigned<br>2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157814, encodeId=e6ed215e81465, content=变成editor appointed的留言统计一下吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57435640187, createdName=koko叩叩, createdTime=Fri Sep 15 10:43:01 CST 2023, time=2023-09-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154512, encodeId=7e702154512b4, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信加细胞功能实验<br>经验分享:8月4号已投稿,8月5号邀请6个审稿人,8月14号1个审稿人接受审稿,现在没消息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=ms8000001459205604, createdTime=Fri Aug 25 11:04:29 CST 2023, time=2023-08-25, status=1, ipAttribution=广西)]
    2023-07-02 Doctor小雷 来自重庆

    偏重的研究方向:肝癌
    经验分享:刚刚一个月 还是 10 reviewers invited

    30

    展开30条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿,10月7日直接接收,还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=471, replyNumber=124, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:Part 1 审稿流程 Part 2 论坛常见问题 审稿流程如下: 2023-06-20 投稿 2023-06-20 技术检查通过,安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受 后续包括编辑初步校对,选择OA还是非OA,最后校对都是在2、3天内完成,效率很高 常见问题 1、文章参考格式:Endnote APA 6th(稍微参考一下既往杂志文章都不会问出这问题) 2、投稿状态的顺序:Under review(稿件进入投稿流程)→Reviewer Accepted(有审稿人开始审你的稿件了)→Reviews report received(编辑收到了审稿人的意见)→Reviewer reports received/ Ready for editor' s decision(所有的审稿人意见都回来之后,才会开始进入编辑审查阶段,等待编辑汇总意见之后会发给你对文章的处理决定) 3、回顾性研究,case report,基础,生信,meta都收录,被秒拒的大多是优先级不够或者没有任何亮点,纯生信不加试验没有亮点凭啥接收呢?杂志审稿人态度还是很端正的,结合审稿意见来看对文章的大方向和细节都是有要求的,没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上,在投稿时把那个选项X掉比较好 5、杂志可以共同通讯,在文章中标注清楚即可 6、在进入审稿流程后,所有的文章动态更新都只有通讯作者邮箱才能收到,第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别,OA文章在增加引用量上有其固有优势,掏钱发文章这种事见仁见智,btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向:肿瘤<br>经验分享:我的文章13号接收的,回来看评论,很多朋友都在问参考文献格式怎么下,说实话,到现在文章被接收我都不知道哪里下,我当时投稿的时候也是找了半天没找到,后来索性找了个施普林格旗下比较类似的文献格式,然后用endnote编辑成JOCR这个样子的,然后投稿了,到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218438, encodeId=49f11218438ff, content=偏重的研究方向:肿瘤;眼科<br>经验分享:2022.5.5晚10点投稿<br>2022.5.6 Quality check passed <br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d564883189, createdName=18344b9fa1m, createdTime=Tue May 10 13:43:22 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向:肝癌<br>经验分享:刚刚一个月 还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2153998, encodeId=04b2215399869, content=偏重的研究方向:肿瘤;胰腺癌<br>经验分享:三周半了还没有邀请到审稿人,肿瘤基础研究,看大家最近都表示审稿人邀请比较慢,想咨询一下后续进度,大概多久能邀请到呢?后续被拒的概率大不大,好怕再等又被拒了,时间紧张。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5468757151, createdName=ms7000001668893774, createdTime=Tue Aug 22 08:50:22 CST 2023, time=2023-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:5.2投稿,5.4技术审查通过;5.4under review;5.9小修,5.11修回,5.12技术审查通过;5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受,因为杂志效率高所以投了,没上5分是个遗憾,写一下时间线吧,贡大家参考<br>临床回顾研究,头颈肿瘤 主编和副编效率一流,审稿人效率也是见过最快的,初审14天,二审7天<br>2021-8-27 new submission<br>2021-9-20 minor revisions<br>2021-10-11 Revision Submitted<br>2021-10-24 reviews completed <br>2021-10-24 editor assigned<br>2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157814, encodeId=e6ed215e81465, content=变成editor appointed的留言统计一下吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57435640187, createdName=koko叩叩, createdTime=Fri Sep 15 10:43:01 CST 2023, time=2023-09-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154512, encodeId=7e702154512b4, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信加细胞功能实验<br>经验分享:8月4号已投稿,8月5号邀请6个审稿人,8月14号1个审稿人接受审稿,现在没消息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=ms8000001459205604, createdTime=Fri Aug 25 11:04:29 CST 2023, time=2023-08-25, status=1, ipAttribution=广西)]
    2023-08-22 ms7000001668893774

    偏重的研究方向:肿瘤;胰腺癌
    经验分享:三周半了还没有邀请到审稿人,肿瘤基础研究,看大家最近都表示审稿人邀请比较慢,想咨询一下后续进度,大概多久能邀请到呢?后续被拒的概率大不大,好怕再等又被拒了,时间紧张。。。

    26

    展开26条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿,10月7日直接接收,还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=471, replyNumber=124, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:Part 1 审稿流程 Part 2 论坛常见问题 审稿流程如下: 2023-06-20 投稿 2023-06-20 技术检查通过,安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受 后续包括编辑初步校对,选择OA还是非OA,最后校对都是在2、3天内完成,效率很高 常见问题 1、文章参考格式:Endnote APA 6th(稍微参考一下既往杂志文章都不会问出这问题) 2、投稿状态的顺序:Under review(稿件进入投稿流程)→Reviewer Accepted(有审稿人开始审你的稿件了)→Reviews report received(编辑收到了审稿人的意见)→Reviewer reports received/ Ready for editor' s decision(所有的审稿人意见都回来之后,才会开始进入编辑审查阶段,等待编辑汇总意见之后会发给你对文章的处理决定) 3、回顾性研究,case report,基础,生信,meta都收录,被秒拒的大多是优先级不够或者没有任何亮点,纯生信不加试验没有亮点凭啥接收呢?杂志审稿人态度还是很端正的,结合审稿意见来看对文章的大方向和细节都是有要求的,没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上,在投稿时把那个选项X掉比较好 5、杂志可以共同通讯,在文章中标注清楚即可 6、在进入审稿流程后,所有的文章动态更新都只有通讯作者邮箱才能收到,第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别,OA文章在增加引用量上有其固有优势,掏钱发文章这种事见仁见智,btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向:肿瘤<br>经验分享:我的文章13号接收的,回来看评论,很多朋友都在问参考文献格式怎么下,说实话,到现在文章被接收我都不知道哪里下,我当时投稿的时候也是找了半天没找到,后来索性找了个施普林格旗下比较类似的文献格式,然后用endnote编辑成JOCR这个样子的,然后投稿了,到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218438, encodeId=49f11218438ff, content=偏重的研究方向:肿瘤;眼科<br>经验分享:2022.5.5晚10点投稿<br>2022.5.6 Quality check passed <br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d564883189, createdName=18344b9fa1m, createdTime=Tue May 10 13:43:22 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向:肝癌<br>经验分享:刚刚一个月 还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2153998, encodeId=04b2215399869, content=偏重的研究方向:肿瘤;胰腺癌<br>经验分享:三周半了还没有邀请到审稿人,肿瘤基础研究,看大家最近都表示审稿人邀请比较慢,想咨询一下后续进度,大概多久能邀请到呢?后续被拒的概率大不大,好怕再等又被拒了,时间紧张。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5468757151, createdName=ms7000001668893774, createdTime=Tue Aug 22 08:50:22 CST 2023, time=2023-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:5.2投稿,5.4技术审查通过;5.4under review;5.9小修,5.11修回,5.12技术审查通过;5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受,因为杂志效率高所以投了,没上5分是个遗憾,写一下时间线吧,贡大家参考<br>临床回顾研究,头颈肿瘤 主编和副编效率一流,审稿人效率也是见过最快的,初审14天,二审7天<br>2021-8-27 new submission<br>2021-9-20 minor revisions<br>2021-10-11 Revision Submitted<br>2021-10-24 reviews completed <br>2021-10-24 editor assigned<br>2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157814, encodeId=e6ed215e81465, content=变成editor appointed的留言统计一下吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57435640187, createdName=koko叩叩, createdTime=Fri Sep 15 10:43:01 CST 2023, time=2023-09-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154512, encodeId=7e702154512b4, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信加细胞功能实验<br>经验分享:8月4号已投稿,8月5号邀请6个审稿人,8月14号1个审稿人接受审稿,现在没消息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=ms8000001459205604, createdTime=Fri Aug 25 11:04:29 CST 2023, time=2023-08-25, status=1, ipAttribution=广西)]
    2023-05-13 wwei0125 来自山东省

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向:肿瘤
    经验分享:5.2投稿,5.4技术审查通过;5.4under review;5.9小修,5.11修回,5.12技术审查通过;5.13接收。效率极高的杂志

    24

    展开24条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿,10月7日直接接收,还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=471, replyNumber=124, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:Part 1 审稿流程 Part 2 论坛常见问题 审稿流程如下: 2023-06-20 投稿 2023-06-20 技术检查通过,安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受 后续包括编辑初步校对,选择OA还是非OA,最后校对都是在2、3天内完成,效率很高 常见问题 1、文章参考格式:Endnote APA 6th(稍微参考一下既往杂志文章都不会问出这问题) 2、投稿状态的顺序:Under review(稿件进入投稿流程)→Reviewer Accepted(有审稿人开始审你的稿件了)→Reviews report received(编辑收到了审稿人的意见)→Reviewer reports received/ Ready for editor' s decision(所有的审稿人意见都回来之后,才会开始进入编辑审查阶段,等待编辑汇总意见之后会发给你对文章的处理决定) 3、回顾性研究,case report,基础,生信,meta都收录,被秒拒的大多是优先级不够或者没有任何亮点,纯生信不加试验没有亮点凭啥接收呢?杂志审稿人态度还是很端正的,结合审稿意见来看对文章的大方向和细节都是有要求的,没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上,在投稿时把那个选项X掉比较好 5、杂志可以共同通讯,在文章中标注清楚即可 6、在进入审稿流程后,所有的文章动态更新都只有通讯作者邮箱才能收到,第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别,OA文章在增加引用量上有其固有优势,掏钱发文章这种事见仁见智,btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向:肿瘤<br>经验分享:我的文章13号接收的,回来看评论,很多朋友都在问参考文献格式怎么下,说实话,到现在文章被接收我都不知道哪里下,我当时投稿的时候也是找了半天没找到,后来索性找了个施普林格旗下比较类似的文献格式,然后用endnote编辑成JOCR这个样子的,然后投稿了,到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218438, encodeId=49f11218438ff, content=偏重的研究方向:肿瘤;眼科<br>经验分享:2022.5.5晚10点投稿<br>2022.5.6 Quality check passed <br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d564883189, createdName=18344b9fa1m, createdTime=Tue May 10 13:43:22 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向:肝癌<br>经验分享:刚刚一个月 还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2153998, encodeId=04b2215399869, content=偏重的研究方向:肿瘤;胰腺癌<br>经验分享:三周半了还没有邀请到审稿人,肿瘤基础研究,看大家最近都表示审稿人邀请比较慢,想咨询一下后续进度,大概多久能邀请到呢?后续被拒的概率大不大,好怕再等又被拒了,时间紧张。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5468757151, createdName=ms7000001668893774, createdTime=Tue Aug 22 08:50:22 CST 2023, time=2023-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:5.2投稿,5.4技术审查通过;5.4under review;5.9小修,5.11修回,5.12技术审查通过;5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受,因为杂志效率高所以投了,没上5分是个遗憾,写一下时间线吧,贡大家参考<br>临床回顾研究,头颈肿瘤 主编和副编效率一流,审稿人效率也是见过最快的,初审14天,二审7天<br>2021-8-27 new submission<br>2021-9-20 minor revisions<br>2021-10-11 Revision Submitted<br>2021-10-24 reviews completed <br>2021-10-24 editor assigned<br>2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157814, encodeId=e6ed215e81465, content=变成editor appointed的留言统计一下吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57435640187, createdName=koko叩叩, createdTime=Fri Sep 15 10:43:01 CST 2023, time=2023-09-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154512, encodeId=7e702154512b4, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信加细胞功能实验<br>经验分享:8月4号已投稿,8月5号邀请6个审稿人,8月14号1个审稿人接受审稿,现在没消息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=ms8000001459205604, createdTime=Fri Aug 25 11:04:29 CST 2023, time=2023-08-25, status=1, ipAttribution=广西)]
    2021-10-25 1469323em90暂无昵称

    昨日凌晨文章接受,因为杂志效率高所以投了,没上5分是个遗憾,写一下时间线吧,贡大家参考
    临床回顾研究,头颈肿瘤 主编和副编效率一流,审稿人效率也是见过最快的,初审14天,二审7天
    2021-8-27 new submission
    2021-9-20 minor revisions
    2021-10-11 Revision Submitted
    2021-10-24 reviews completed
    2021-10-24 editor assigned
    2021-10-24 accept

    23

    展开23条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿,10月7日直接接收,还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=471, replyNumber=124, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:Part 1 审稿流程 Part 2 论坛常见问题 审稿流程如下: 2023-06-20 投稿 2023-06-20 技术检查通过,安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受 后续包括编辑初步校对,选择OA还是非OA,最后校对都是在2、3天内完成,效率很高 常见问题 1、文章参考格式:Endnote APA 6th(稍微参考一下既往杂志文章都不会问出这问题) 2、投稿状态的顺序:Under review(稿件进入投稿流程)→Reviewer Accepted(有审稿人开始审你的稿件了)→Reviews report received(编辑收到了审稿人的意见)→Reviewer reports received/ Ready for editor' s decision(所有的审稿人意见都回来之后,才会开始进入编辑审查阶段,等待编辑汇总意见之后会发给你对文章的处理决定) 3、回顾性研究,case report,基础,生信,meta都收录,被秒拒的大多是优先级不够或者没有任何亮点,纯生信不加试验没有亮点凭啥接收呢?杂志审稿人态度还是很端正的,结合审稿意见来看对文章的大方向和细节都是有要求的,没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上,在投稿时把那个选项X掉比较好 5、杂志可以共同通讯,在文章中标注清楚即可 6、在进入审稿流程后,所有的文章动态更新都只有通讯作者邮箱才能收到,第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别,OA文章在增加引用量上有其固有优势,掏钱发文章这种事见仁见智,btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向:肿瘤<br>经验分享:我的文章13号接收的,回来看评论,很多朋友都在问参考文献格式怎么下,说实话,到现在文章被接收我都不知道哪里下,我当时投稿的时候也是找了半天没找到,后来索性找了个施普林格旗下比较类似的文献格式,然后用endnote编辑成JOCR这个样子的,然后投稿了,到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218438, encodeId=49f11218438ff, content=偏重的研究方向:肿瘤;眼科<br>经验分享:2022.5.5晚10点投稿<br>2022.5.6 Quality check passed <br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d564883189, createdName=18344b9fa1m, createdTime=Tue May 10 13:43:22 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向:肝癌<br>经验分享:刚刚一个月 还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2153998, encodeId=04b2215399869, content=偏重的研究方向:肿瘤;胰腺癌<br>经验分享:三周半了还没有邀请到审稿人,肿瘤基础研究,看大家最近都表示审稿人邀请比较慢,想咨询一下后续进度,大概多久能邀请到呢?后续被拒的概率大不大,好怕再等又被拒了,时间紧张。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5468757151, createdName=ms7000001668893774, createdTime=Tue Aug 22 08:50:22 CST 2023, time=2023-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:5.2投稿,5.4技术审查通过;5.4under review;5.9小修,5.11修回,5.12技术审查通过;5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受,因为杂志效率高所以投了,没上5分是个遗憾,写一下时间线吧,贡大家参考<br>临床回顾研究,头颈肿瘤 主编和副编效率一流,审稿人效率也是见过最快的,初审14天,二审7天<br>2021-8-27 new submission<br>2021-9-20 minor revisions<br>2021-10-11 Revision Submitted<br>2021-10-24 reviews completed <br>2021-10-24 editor assigned<br>2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157814, encodeId=e6ed215e81465, content=变成editor appointed的留言统计一下吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57435640187, createdName=koko叩叩, createdTime=Fri Sep 15 10:43:01 CST 2023, time=2023-09-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154512, encodeId=7e702154512b4, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信加细胞功能实验<br>经验分享:8月4号已投稿,8月5号邀请6个审稿人,8月14号1个审稿人接受审稿,现在没消息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=ms8000001459205604, createdTime=Fri Aug 25 11:04:29 CST 2023, time=2023-08-25, status=1, ipAttribution=广西)]
    2023-09-15 koko叩叩 来自广东省

    变成editor appointed的留言统计一下吧

    22

    展开22条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿,10月7日直接接收,还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=471, replyNumber=124, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤<br>经验分享:Part 1 审稿流程 Part 2 论坛常见问题 审稿流程如下: 2023-06-20 投稿 2023-06-20 技术检查通过,安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受 后续包括编辑初步校对,选择OA还是非OA,最后校对都是在2、3天内完成,效率很高 常见问题 1、文章参考格式:Endnote APA 6th(稍微参考一下既往杂志文章都不会问出这问题) 2、投稿状态的顺序:Under review(稿件进入投稿流程)→Reviewer Accepted(有审稿人开始审你的稿件了)→Reviews report received(编辑收到了审稿人的意见)→Reviewer reports received/ Ready for editor' s decision(所有的审稿人意见都回来之后,才会开始进入编辑审查阶段,等待编辑汇总意见之后会发给你对文章的处理决定) 3、回顾性研究,case report,基础,生信,meta都收录,被秒拒的大多是优先级不够或者没有任何亮点,纯生信不加试验没有亮点凭啥接收呢?杂志审稿人态度还是很端正的,结合审稿意见来看对文章的大方向和细节都是有要求的,没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上,在投稿时把那个选项X掉比较好 5、杂志可以共同通讯,在文章中标注清楚即可 6、在进入审稿流程后,所有的文章动态更新都只有通讯作者邮箱才能收到,第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别,OA文章在增加引用量上有其固有优势,掏钱发文章这种事见仁见智,btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向:肿瘤<br>经验分享:我的文章13号接收的,回来看评论,很多朋友都在问参考文献格式怎么下,说实话,到现在文章被接收我都不知道哪里下,我当时投稿的时候也是找了半天没找到,后来索性找了个施普林格旗下比较类似的文献格式,然后用endnote编辑成JOCR这个样子的,然后投稿了,到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218438, encodeId=49f11218438ff, content=偏重的研究方向:肿瘤;眼科<br>经验分享:2022.5.5晚10点投稿<br>2022.5.6 Quality check passed <br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d564883189, createdName=18344b9fa1m, createdTime=Tue May 10 13:43:22 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2146006, encodeId=9a6a214600677, content=偏重的研究方向:肝癌<br>经验分享:刚刚一个月 还是 10 reviewers invited, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Sun Jul 02 22:56:21 CST 2023, time=2023-07-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2153998, encodeId=04b2215399869, content=偏重的研究方向:肿瘤;胰腺癌<br>经验分享:三周半了还没有邀请到审稿人,肿瘤基础研究,看大家最近都表示审稿人邀请比较慢,想咨询一下后续进度,大概多久能邀请到呢?后续被拒的概率大不大,好怕再等又被拒了,时间紧张。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5468757151, createdName=ms7000001668893774, createdTime=Tue Aug 22 08:50:22 CST 2023, time=2023-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:5.2投稿,5.4技术审查通过;5.4under review;5.9小修,5.11修回,5.12技术审查通过;5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受,因为杂志效率高所以投了,没上5分是个遗憾,写一下时间线吧,贡大家参考<br>临床回顾研究,头颈肿瘤 主编和副编效率一流,审稿人效率也是见过最快的,初审14天,二审7天<br>2021-8-27 new submission<br>2021-9-20 minor revisions<br>2021-10-11 Revision Submitted<br>2021-10-24 reviews completed <br>2021-10-24 editor assigned<br>2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157814, encodeId=e6ed215e81465, content=变成editor appointed的留言统计一下吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57435640187, createdName=koko叩叩, createdTime=Fri Sep 15 10:43:01 CST 2023, time=2023-09-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2154512, encodeId=7e702154512b4, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信加细胞功能实验<br>经验分享:8月4号已投稿,8月5号邀请6个审稿人,8月14号1个审稿人接受审稿,现在没消息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=912a8743402, createdName=ms8000001459205604, createdTime=Fri Aug 25 11:04:29 CST 2023, time=2023-08-25, status=1, ipAttribution=广西)]
    2023-08-25 ms8000001459205604 来自广西

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向:肿瘤;生信加细胞功能实验
    经验分享:8月4号已投稿,8月5号邀请6个审稿人,8月14号1个审稿人接受审稿,现在没消息了

    22

    展开22条回复
共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分